**Name of Journal:** *World Journal of* *Gastroenterology*

**Manuscript NO:** 48664

**Manuscript Type:** EDITORIAL

**Hepatocellular carcinoma and metabolic syndrome: The times are changing and so should we**

Tsoulfas G. HCC and metabolic syndrome

Georgios Tsoulfas

**Georgios Tsoulfas,** Department of Surgery, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece

**ORCID number:** Georgios Tsoulfas (0000-0001-5043-7962).

**Author contributions:** Tsoulfas G interpreted the literature and wrote the manuscript.

**Conflict-of-interest statement:** Georgios Tsoulfas reports no conflict of interest.

**Open-Access**: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Corresponding author: Georgios Tsoulfas, FACS, FICS, MD, PhD, Associate Professor,** Department of Surgery, Aristotle University of Thessaloniki, University Campus, Thessaloniki 54124, Greece. tsoulfasg@auth.gr

**Telephone:** +30-697189190

**Fax:** +30-2310-3320222

**Received:** April 28, 2019

**Peer-review started:** April 28, 2019

**First decision:** May 24, 2019

**Revised:** June 3, 2019

**Accepted:** June 25, 2019

**Article in press:** June 26, 2019

**Published online:** August 7, 2019

**Abstract**

Although hepatocellular carcinoma (HCC) is as prevalent as ever as a cancer-related mortality, and some would even argue that it is increasing, the pattern of its etiologies has been changing. Specifically, the domination of viral hepatitis C virus is being overcome, partly because of the emergence of the antiviral treatments, and partly because of the significant increase, especially in developed countries, of the combination of obesity, diabetes, metabolic syndrome, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. This editorial will explore the interconnection of this group of diseases and how they are linked to HCC. More importantly, it will argue that this shift in HCC etiology essentially means that we have to change how we approach the treatment of HCC, by changing our focus (and resources) to earlier stages of the disease development in order to prevent the appearance and progression of HCC.

**Key words**: Hepatocellular carcinoma; Diabetes; Obesity; Steatosis; Non-alcoholic fatty liver disease; Body-mass index; Non-alcoholic steatohepatitis

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** There is a changing landscape whereby metabolic syndrome and non-alcoholic fatty liver disease and non-alcoholic steatohepatitis have replaced hepatitis viral infections and alcohol as the predominant causes of cirrhosis and hepatocellular carcinoma (HCC) on the global scale. As such, we need to change the treatment focus and address metabolic syndrome and its elements in an effort to intervene more timely in the development of cirrhosis and HCC.

**Citation**: Tsoulfas G. Hepatocellular carcinoma and metabolic syndrome: The times are changing and so should we. *World J Gastroenterol* 2019; 25(29): 3842-3848 Available from: **URL**: https://www.wjgnet.com/1007-9327/full/v25/i29/3842.htm

**DOI**: https://dx.doi.org/10.3748/wjg.v25.i29.3842

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver, whereas among all types of cancers HCC is the fifth most common with an aggressive nature that had it ranking second in 2012 in terms of causes of cancer-related death in the world[1,2]. The prevalence and aggressiveness of HCC have led to a world-wide interest and an increasingly multidisciplinary approach with the use of new technologies and molecular analysis with the hope of achieving a more patient-targeted approach. From a surgical standpoint, the armamentarium available has been increasing with examples such as hepatic resection, microwave or radiofrequency ablation, transarterial chemoembolization, irreversible electroporation, and of course liver transplantation (LT). The latter is especially important as HCC frequently coexists with cirrhosis and LT represents a treatment for both. Unfortunately, the lack of donors has led to efforts to expand the donor pool with the use of Donors after Cardiac Death, split grafts, living related and expanded criteria grafts, all of which necessitate careful donor and recipient selection and matching. Despite all these efforts, HCC remains a formidable opponent and the only significant victory that we have been able to enjoy in this last decade is the advent of the latest all oral, ribavirin- and interferon-free regimens of direct acting antivirals against the hepatitis C virus (HCV) which have achieved 90% sustained virological response, which is essentially a cure[3]. The fact that this is for all genotypes, has led to LT actually providing a cure for HCV, rather than a short interlude from an aggressive recurrence; at the same time, it is part of a big change in the landscape of HCC etiology and management.

**CHANGING LANDSCAPE OF HCC**

Specifically, the progress having to do with the HCV epidemic and the persistent increase in obesity, diabetes, non-alcoholic steatohepatitis (NASH), and non-alcoholic fatty liver disease (NAFLD) have allowed metabolic syndrome (MetS) to take the reins regarding factors and diseases affecting the liver and eventually leading to HCC[4].

***Defining NAFLD and NASH***

Before proceeding any further it is important to present some of the definitions of the terms used. The reason is that very frequently the term NAFLD is associated and may be used interchangeably with the other terms such as NASH or “hepatic steatosis”, which is not correct as there are significant differences with clinical implications. The term “hepatic steatosis” refers to the presence of micro- or macro- or mixed vesicular fat in the cytoplasm of the hepatocytes[5]. Using the American Association for the Study of Liver Diseases guidelines for the definition of NAFLD we need to establish primary hepatic steatosis (confirmed either by imaging or biopsy), while at the same time exclude any secondary causes of hepatic steatosis (medications, alcohol, hereditary)[6]. NASH represents an extension of NAFLD, whereby the presence of primary hepatic steatosis (need more than 5%) leads to inflammation and hepatocellular injury (ballooning), and is the form that can actually progress to fibrosis, cirrhosis and HCC[7]. Today, NAFLD represents the most common chronic liver disease worldwide. It constitutes an epidemic with prevalence in adults in developed countries somewhere between 30%-50%, with the main obstacle in finding a more concise measurement being the difficulties in the diagnostic methods between the different studies[8-10]. NAFLD is frequently associated with obesity, type II diabetes mellitus (T2DM), and dyslipidemia, all of which are components of the MetS[11,12]. The definition of MetS developed over time and through different medical associations, such as the International Diabetes Federation (IDF), World Health Organization and the United States National Cholesterol Education program Adult Treatment Panel. Eventually this led to the Harmonized (consensus) definition in 2009 incorporating those of the IDF and the American Heart Association, which includes any three of the following: (1) Waist circumference: According to population and country-specific definitions; (2) triglycerides: ≥ 150 mg/dL (1.7 mmol/L); (3) high density lipoprotien cholesterol: < 40 mg/dL (1.03 mmol/L) in men and < 50 mg/dL (1.29 mmol/L) in women; (d) blood pressure: ≥ 130 mmHg systolic; ≥ 85 mmHg diastolic; and (5) fasting glucose: ≥ 100 mg/dL (5.6 mmol/L) or use of medication[13].

***Epidemiology of NAFLD and NASH***

The relation between NAFLD, and as an extension NASH, and MetS is a complex one. In the past, NAFLD was viewed as the hepatic component of MetS given its relationship with obesity and insulin resistance. Over time we have essentially seen that this is a two-way street, as on the one hand NAFLD can lead to T2DM and its relation to obesity and the lipid abnormalities combined with the hepatic inflammation can lead to MetS. On the other hand, the various manifestations of MetS can lead to a deterioration of NAFLD and move towards NASH, fibrosis, cirrhosis and eventually HCC[13,14]. As complex as the relationship between NAFLD/NASH and MetS may seem, that of NAFLD/NASH to HCC is a much more straightforward one. Currently, NAFLD-related cirrhosis or NAFLD-related HCC are the second cause of LT in the United States, whereas NAFLD is responsible for somewhere between 5%-20% of HCC cases in the Western world[15,16]. This is depicted in an excellent study by Younossi *et al*[17] who aim to identify the global prevalence of NAFLD and NASH, while at the same time describing their natural history and progression. By looking at reports between the years 1989 and 2015, they arrive at three main conclusions: (1) There is a significant global burden of NASH and a global prevalence of NAFLD of 25% with a geographical variation. This last point could have to do with genetic and cultural differences which can certainly play a role in shaping body mass; (2) the progression of fibrosis that can be seen in NAFLD and NASH is very slow with these patients having a > 50% chance of non-liver related mortality[17]. The incidence of HCC among NAFLD patients is very low at a frequency of 0.44/1000 person-years; however, the prevalence of NAFLD in the population makes up for that, and as a result NAFLD by affecting over 1 billion adults world-wide remains a basic cause of LT[18]; and (3) despite the fact that liver-related events may be responsible for only a small fraction of deaths in NAFLD and NASH patients, NASH is rapidly becoming the most common etiology of liver-related death globally.

The above findings present an association between a metabolic disease predominantly and a type of cancer. This is quite intriguing, especially if we consider that the mechanism is not completely clear. Alterations in gene expressions may play a significant role, as a high number of them were observed during the progression from steatosis to NASH, with special emphasis on the fibrosis and inflammation aspects[19]. As part of this progression towards cirrhosis and, eventually, HCC, extracellular matrix and angiogenesis genes are up regulated, whereas others that affect iron homeostasis are down regulated[20]. A central part of the evolution of NASH, at the molecular level, is the down regulation of the Wnt signaling pathway, as Wnt inhibitors are up regulated[21]. This is directly related to HCC, as dysregulated activation of Wnt signaling has been linked to HCC subclasses[21].

**OBESITY**

Obesity represents a common denominator between NAFLD/NASH and MetS, and as such deserves special mention. At first its role seems quite straightforward as the association of obesity with T2DM and cardiovascular disease are expected to present a risk to a person’s health. This may lead us to believe that the mere presence of obesity should lead to higher morbidity and mortality; yet, there have been several studies using data from the National Surgical Quality Improvement Program of the American College of Surgeons which have failed to find a correlation between obesity and mortality in surgical patients[22,23]. This has also been the case with studies in general or colorectal surgery, leading to the term “obesity paradox”, in order to describe the unexpected protective effect of obesity[24,25]. Part of the explanation for this may be the existence of different definitions for obesity and corpulence, as well as the different distributions of fat in either adipose subcutaneous tissue or visceral obesity[26,27]. Either way, the above should not distract from the fact that abdominal obesity is directly linked to MetS, with its variables including visceral obesity, insulin resistance, dyslipidemia and systemic hypertension[28]. Furthermore, obesity is linked to NASH, which is also closely associated with MetS, thus bringing everything to a full circle. The relation between MetS and NASH with obesity as the “go-between” has led to NASH becoming the fastest growing indication for LT in the US, with a prediction that by 2025 approximately 25 million Americans will have developed NASH, a fifth of whom may need to undergo transplantation[29,30]. If that were not enough, in those patients undergoing LT, the prevalence of NASH after 6 months is around 50%-60%, as opposed to 23% in the general population[31,32]. The main explanation for this is the immunosuppressive medications and their side-effects. However, what is significant is the fact that the presence of MetS post-transplantation is predictive of NASH recurrence, which can jeopardize the graft and the patient’s life[33,34].

Overall, we are seeing a paradigm shift where NAFLD/NASH and MetS are steadily replacing hepatitis viral infections (usually HCV) as the main cause of HCC and the second most frequent one for LT. Although the underlying mechanism of the progression from MetS and NAFLD/NASH to HCC is not fully understood, possibilities include the generation of reactive oxygen species, the presence of leptin (a proinflammatory cytokine with angiogenic abilities), the mild yet persistent inflammation state seen in obesity, which may all affect cellular transcription and signaling, thus leading to the appearance of HCC[35,36].

**TREATMENT**

This paradigm shift that we have seen, which essentially signifies that MetS, through NAFLD/NASH, now represents the main pathway to HCC and cirrhosis, has several connotations for treatment. Specifically, it means that a significant part of our efforts should be towards preventing HCC and cirrhosis, rather than waiting for them to happen and then have to deal with complicated and costly treatments. Efforts should start focusing at dealing with MetS, which mean addressing its main components such as DM, hypertension, dyslipidemia, obesity and through those the effects of NASH and NAFLD. The following are some important parts of this treatment plan and include:

***Lifestyle changes***

Weight loss is key in managing all the different elements of MetS, such as obesity, hypertension, dyslipidemia and T2DM, as well as in helping to control NAFLD and its progression to NASH[37-39]. This implies a combination of decreased caloric intake, as well as increased physical activity, especially walking. Although there is no consensus as to the specifics of the weight loss, there is agreement that it should be steady.

***Pharmacologic therapy***

The intimate causal relationship (possibly in all directions) between MetS, NAFLD/NASH and T2DM has caused a lot of interest in medications, such as metformin and pioglitazone. Metformin, together with the lifestyle changes, is believed to be especially appropriate for patients with T2DM and NAFLD or early NASH, although it has not been shown to have a beneficial effect on liver histology[40,41]. Pioglitazone, belonging in the thiazolidinediones category of medications that cause an upregulation of the genes involved in glucose metabolism, resulting in decreased hepatic lipogenesis, thus leading to improved glucose tolerance and decreased hepatic inflammation and avoidance of NASH[42,43]. The main limitations have been the need for long-term treatment and the side-effects which include congestive heart failure and stroke among others[44]. Well-established medical treatments currently exist also for hypertension and dyslipidemia, which in certain instances, such as the use of statins, have been shown to affect in a positive manner the prevention and progression of cirrhosis and HCC[45].

***Nutrition therapy***

Although the question of whether NAFLD and the progression to NASH is a matter of overnutrition or simply the result of a “different” nutritional pattern with different responses from the metabolic system, there is no good data on what the proper diet specifically for NAFLD/NASH patients should be. The closest to a recommendation are those originating from the American Diabetes Association and the American Heart Association, given the prevalence and importance in the whole process of T2DM and cardiovascular disease[46].

***Bariatric surgery***

There have been significant advances in bariatric surgery, especially pertaining to identifying the best type of surgery for the specific patient. The recognition of MetS, as well as the effect that we have witnessed bariatric surgery having on T2DM and hypertension, have led to bariatric surgery taking a central role in the management of MetS. There are several procedures such as the adjustable gastric banding, the sleeve gastrectomy, the Roux-en-Y gastric bypass, the duodenal switch or biliopancreatic diversion with all of them having different amounts of restrictive and malabsorptive elements[47]. The advances in minimally invasive surgery have also made these procedures more physiologically “attractive” for these patients. As potentially useful as bariatric surgery can be, it needs to be stressed that it is not enough by itself to avoid the combined ill effects of MetS and especially those pertaining to NAFLD/NASH and the HCC progression; the reason is that the main therapy for MetS remains more a matter of lifestyle adjustments/change, rather than surgical treatment.

**CONCLUSION**

The goal of this editorial is to hopefully change the mindset of how we approach cirrhosis and HCC. Specifically, by recognizing the importance of MetS, NAFLD and NASH and the combined role that they play in the progression to fibrosis, cirrhosis and eventually HCC, can help us shift the focus from the management of HCC once it has appeared with challenging and costly procedures and interventions, to the avoidance or management of MetS and its elements with the methods previously described. Additionally, we need to change the way that we have been approaching obesity as the result of bad lifestyle choices and realize that it is a multidimensional disease affecting several organ systems and where successful management requires a spectrum of interventions ranging from public education and preventive care to medications and bariatric surgery. In summary, MetS and NAFLD and their association with NASH, T2DM, hypertension, obesity and cardiovascular disease are all part of an equation which explains today (more than any other cause) the progression of chronic liver disease to cirrhosis and, eventually, to HCC. Once we understand this, we can start changing or adjusting the focus of our interventions for cirrhosis and HCC by placing emphasis on an earlier part of the disease spectrum where all these factors are at play; ultimately, the goal is to prevent than to have to treat.

**REFERENCES**

1 **Ferlay J**, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010; **127**: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]

2 GLOBOCAN. Estimated cancer incidence: Mortality and prevalence worldwide in 2012. Available from: http:// globocan.iarc.fr/Pages/fact\_sheets\_cancer.aspx

3 **Fobi M**. Metabolic surgery: Procedures vary internationally. Metabolic Surgery and International Practice by ACS. *Bull Am Coll Surg* 2019

4 **Caldwell SH**, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. *Gastroenterology* 2004; **127**: S97-103 [PMID: 15508109 DOI: 10.1053/j.gastro.2004.09.021]

5 **Burt AD**, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. *Semin Diagn Pathol* 1998; **15**: 246-258 [PMID: 9845426]

6 **Chalasani N**, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology* 2012; **142**: 1592-1609 [PMID: 22656328 DOI: 10.1053/j.gastro.2012.04.001]

7 **Hellerbrand C**. Pathophysiological similarities and synergisms in alcoholic and non-alcoholic steatohepatitis. *Dig Dis* 2010; **28**: 783-791 [PMID: 21525763 DOI: 10.1159/000324286]

8 **Browning JD**, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. *Hepatology* 2004; **40**: 1387-1395 [PMID: 15565570 DOI: 10.1002/hep.20466]

9 **Williams CD**, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. *Gastroenterology* 2011; **140**: 124-131 [PMID: 20858492 DOI: 10.1053/j.gastro.2010.09.038]

10 **Bellentani S**, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. *Dig Dis* 2010; **28**: 155-161 [PMID: 20460905 DOI: 10.1159/000282080]

11 **Fujioka K**. Current and emerging medications for overweight or obesity in people with comorbidities. *Diabetes Obes Metab* 2015; **17**: 1021-1032 [PMID: 26040215 DOI: 10.1111/dom.12502]

12 **VanWagner LB**, Rinella ME. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. *Curr Hepatol Rep* 2016; **15**: 75-85 [PMID: 27218012 DOI: 10.1007/s11901-016-0295-9]

13 **Anstee QM**, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nat Rev Gastroenterol Hepatol* 2013; **10**: 330-344 [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41]

14 **Naik A**, Belič A, Zanger UM, Rozman D. Molecular Interactions between NAFLD and Xenobiotic Metabolism. *Front Genet* 2013; **4**: 2 [PMID: 23346097 DOI: 10.3389/fgene.2013.00002]

15 **Bellentani S**. The epidemiology of non-alcoholic fatty liver disease. *Liver Int* 2017; **37 Suppl 1**: 81-84 [PMID: 28052624 DOI: 10.1111/liv.13299]

16 **White DL**, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. *Clin Gastroenterol Hepatol* 2012; **10**: 1342-1359.e2 [PMID: 23041539 DOI: 10.1016/j.cgh.2012.10.001]

17 **Younossi ZM**, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology* 2016; **64**: 73-84 [PMID: 26707365 DOI: 10.1002/hep.28431]

18 **Angulo P**, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology* 2015; **149**: 389-97.e10 [PMID: 25935633 DOI: 10.1053/j.gastro.2015.04.043]

19 **Lake AD**, Novak P, Fisher CD, Jackson JP, Hardwick RN, Billheimer DD, Klimecki WT, Cherrington NJ. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. *Drug Metab Dispos* 2011; **39**: 1954-1960 [PMID: 21737566 DOI: 10.1124/dmd.111.040592]

20 **Clarke JD**, Novak P, Lake AD, Shipkova P, Aranibar N, Robertson D, Severson PL, Reily MD, Futscher BW, Lehman-McKeeman LD, Cherrington NJ. Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease. *Dig Dis Sci* 2014; **59**: 365-374 [PMID: 24048683 DOI: 10.1007/s10620-013-2873-9]

21 **Hoshida Y**, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, Golub TR. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. *Cancer Res* 2009; **69**: 7385-7392 [PMID: 19723656 DOI: 10.1158/0008-5472.CAN-09-1089]

22 **Al-Refaie WB**, Parsons HM, Henderson WG, Jensen EH, Tuttle TM, Rothenberger DA, Kellogg TA, Virnig BA. Body mass index and major cancer surgery outcomes: Lack of association or need for alternative measurements of obesity? *Ann Surg Oncol* 2010; **17**: 2264-2273 [PMID: 20309642 DOI: 10.1245/s10434-010-1023-2]

23 **Davenport DL**, Xenos ES, Hosokawa P, Radford J, Henderson WG, Endean ED. The influence of body mass index obesity status on vascular surgery 30-day morbidity and mortality. *J Vasc Surg* 2009; **49**: 140-147, 147.e1; discussion 147 [PMID: 19028047 DOI: 10.1016/j.jvs.2008.08.052]

24 **Mullen JT**, Moorman DW, Davenport DL. The obesity paradox: Body mass index and outcomes in patients undergoing nonbariatric general surgery. *Ann Surg* 2009; **250**: 166-172 [PMID: 19561456 DOI: 10.1097/SLA.0b013e3181ad8935]

25 **Dindo D**, Muller MK, Weber M, Clavien PA. Obesity in general elective surgery. *Lancet* 2003; **361**: 2032-2035 [PMID: 12814714 DOI: 10.1016/S0140-6736(03)13640-9]

26 **Yusuf S**, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P Jr, Razak F, Sharma AM, Anand SS; INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: A case-control study. *Lancet* 2005; **366**: 1640-1649 [PMID: 16271645 DOI: 10.1016/S0140-6736(05)67663-5]

27 **Blackett PR**, Sanghera DK. Genetic determinants of cardiometabolic risk: A proposed model for phenotype association and interaction. *J Clin Lipidol* 2013; **7**: 65-81 [PMID: 23351585 DOI: 10.1016/j.jacl.2012.04.079]

28 **Cornier MA**, Després JP, Davis N, Grossniklaus DA, Klein S, Lamarche B, Lopez-Jimenez F, Rao G, St-Onge MP, Towfighi A, Poirier P; American Heart Association Obesity Committee of the Council on Nutrition; Physical Activity and Metabolism; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing, Council on Epidemiology and Prevention; Council on the Kidney in Cardiovascular Disease, and Stroke Council. Assessing adiposity: A scientific statement from the American Heart Association. *Circulation* 2011; **124**: 1996-2019 [PMID: 21947291 DOI: 10.1161/CIR.0b013e318233bc6a]

29 **Singal AK**, Guturu P, Hmoud B, Kuo YF, Salameh H, Wiesner RH. Evolving frequency and outcomes of liver transplantation based on etiology of liver disease. *Transplantation* 2013; **95**: 755-760 [PMID: 23370710 DOI: 10.1097/TP.0b013e31827afb3a]

30 **Agopian VG**, Kaldas FM, Hong JC, Whittaker M, Holt C, Rana A, Zarrinpar A, Petrowsky H, Farmer D, Yersiz H, Xia V, Hiatt JR, Busuttil RW. Liver transplantation for nonalcoholic steatohepatitis: The new epidemic. *Ann Surg* 2012; **256**: 624-633 [PMID: 22964732 DOI: 10.1097/SLA.0b013e31826b4b7e]

31 **Bianchi G**, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: Relation to etiology and immunosuppression. *Liver Transpl* 2008; **14**: 1648-1654 [PMID: 18975273 DOI: 10.1002/lt.21588]

32 **Ford ES**, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. *JAMA* 2002; **287**: 356-359 [PMID: 11790215 DOI: 10.1001/jama.287.3.356]

33 **Malik SM**, Devera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. *Liver Transpl* 2009; **15**: 1843-1851 [PMID: 19938117 DOI: 10.1002/lt.21943]

34 **El Atrache MM**, Abouljoud MS, Divine G, Yoshida A, Kim DY, Kazimi MM, Moonka D, Huang MA, Brown K. Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome. *Clin Transplant* 2012; **26**: E505-E512 [PMID: 23061759 DOI: 10.1111/ctr.12014]

35 **Stickel F**, Hellerbrand C. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: Mechanisms and implications. *Gut* 2010; **59**: 1303-1307 [PMID: 20650925 DOI: 10.1136/gut.2009.199661]

36 **Vinciguerra M**, Carrozzino F, Peyrou M, Carlone S, Montesano R, Benelli R, Foti M. Unsaturated fatty acids promote hepatoma proliferation and progression through downregulation of the tumor suppressor PTEN. *J Hepatol* 2009; **50**: 1132-1141 [PMID: 19398230 DOI: 10.1016/j.jhep.2009.01.027]

37 **Suzuki A**, Lindor K, St Saver J, Lymp J, Mendes F, Muto A, Okada T, Angulo P. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. *J Hepatol* 2005; **43**: 1060-1066 [PMID: 16140415 DOI: 10.1016/j.jhep.2005.06.008]

38 **Lazo M**, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, Wagenknecht LE, Pi-Sunyer FX, Kahn SE, Clark JM; Fatty Liver Subgroup of the Look AHEAD Research Group. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. *Diabetes Care* 2010; **33**: 2156-2163 [PMID: 20664019 DOI: 10.2337/dc10-0856]

39 **Sullivan S**, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. *Hepatology* 2012; **55**: 1738-1745 [PMID: 22213436 DOI: 10.1002/hep.25548]

40 **Nair S**, Diehl AM, Wiseman M, Farr GH Jr, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: A pilot open label trial. *Aliment Pharmacol Ther* 2004; **20**: 23-28 [PMID: 15225167 DOI: 10.1111/j.1365-2036.2004.02025.x]

41 **Haukeland JW**, Konopski Z, Eggesbø HB, von Volkmann HL, Raschpichler G, Bjøro K, Haaland T, Løberg EM, Birkeland K. Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial. *Scand J Gastroenterol* 2009; **44**: 853-860 [PMID: 19811343 DOI: 10.1080/00365520902845268]

42 **Smith U**. Pioglitazone: Mechanism of action. *Int J Clin Pract Suppl* 2001; **(121)**: 13-18 [PMID: 11594239 DOI: 10.1016/S1567-5769(01)00109-6]

43 **Belfort R**, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. *N Engl J Med* 2006; **355**: 2297-2307 [PMID: 17135584 DOI: 10.1056/NEJMoa060326]

44 **Lu CJ**, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY. Risk of stroke with thiazolidinediones: A ten-year nationwide population-based cohort study. *Cerebrovasc Dis* 2013; **36**: 145-151 [PMID: 24029780 DOI: 10.1159/000353679]

45 **Vargas JI**, Arrese M, Shah VH, Arab JP. Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects. *Curr Gastroenterol Rep* 2017; **19**: 43 [PMID: 28752475 DOI: 10.1007/s11894-017-0584-7]

46 **Conlon BA**, Beasley JM, Aebersold K, Jhangiani SS, Wylie-Rosett J. Nutritional management of insulin resistance in nonalcoholic fatty liver disease (NAFLD). *Nutrients* 2013; **5**: 4093-4114 [PMID: 24152749 DOI: 10.3390/nu5104093]

47 **Ayloo S**, Armstrong J, Hurton S, Molinari M. Obesity and liver transplantation. *World J Transplant* 2015; **5**: 95-101 [PMID: 26421262 DOI: 10.5500/wjt.v5.i3.95]

**P-Reviewer:** Chen GX, Kamimura K, Lleo A, Vorobjova T **S-Editor:** Yan JP

**L-Editor:**  A**E-Editor:** Ma YJ

**Specialty type:** Gastroenterology and hepatology   
**Country of origin:** Greece  
**Peer-review report classification**  
**Grade A (Excellent):** A, A  
**Grade B (Very good):** B  
**Grade C (Good):** C  
**Grade D (Fair):** 0 **Grade E (Poor):** 0